Soma and Rhabdomyolysis - a phase IV clinical study of FDA data

Summary:

Rhabdomyolysis is reported as a side effect among people who take Soma (carisoprodol), especially for people who are female, 40-49 old, also take Valium, and have Arthritis.

The phase IV clinical study analyzes which people have Rhabdomyolysis when taking Soma. It is created by eHealthMe based on reports of 15,632 people who have side effects when taking Soma from the FDA, and is updated regularly.

What is Soma?

Soma has active ingredients of carisoprodol. It is often used in muscle spasms. eHealthMe is studying from 17,137 Soma users. Check the latest studies of Soma.

What is Rhabdomyolysis?

Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down) is found to be associated with 1,554 drugs and 1,922 conditions by eHealthMe. Check the latest studies of Rhabdomyolysis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

15,632 people reported to have side effects when taking Soma.
Among them, 80 people (0.51%) have Rhabdomyolysis.

Among these 80 people:

What is the gender of people who have Rhabdomyolysis when taking Soma? *

female: 50.63 %
male: 49.37 %

What is the age of people who have Rhabdomyolysis when taking Soma? *

What are other drugs people take besides Soma? *

What are other side effects people have besides Rhabdomyolysis? *

Acute Kidney Failure: 36 people, 45.00%
Dehydration (dryness resulting from the removal of water): 32 people, 40.00%
Fall: 32 people, 40.00%
Stress And Anxiety: 29 people, 36.25%
Pneumonia: 26 people, 32.50%
Joint Pain: 26 people, 32.50%
Chest Pain: 25 people, 31.25%
Neuropathy Peripheral (surface nerve damage): 25 people, 31.25%
Injury: 22 people, 27.50%
Weakness: 17 people, 21.25%

What are the existing conditions these people have? *

Arthritis (form of joint disorder that involves inflammation of one or more joints): 14 people, 17.50%
Spinal Fracture (fracture in one of vertebrae): 12 people, 15.00%
Neuropathy Peripheral (surface nerve damage): 12 people, 15.00%
Lipids Increased (excess lipid in body): 12 people, 15.00%
Fibromyalgia (a long-term condition which causes pain all over the body): 12 people, 15.00%
Depression: 10 people, 12.50%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 6.25%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 6.25%
High Blood Pressure: 4 people, 5.00%
Sleep Disorder: 4 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Soma and have Rhabdomyolysis?

- Check whether Rhabdomyolysis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Soma:

Soma (17,137 reports)

Rhabdomyolysis treatments and more:

Rhabdomyolysis (60,893 reports)

Browse all side effects of Soma:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rhabdomyolysis:

Rhabdomyolysis (1,554 drugs)

Browse all the conditions that are associated with Rhabdomyolysis:

Rhabdomyolysis (1,922 conditions)

Related publications that referenced our studies

Rezigh, A. B., Armenia, E., Li, T., & Soesilo, I. , "Rifaximin as a rare cause of rhabdomyolysis in cirrhosis", Clinical case reports, 2018 Jan .
Moye, P. M., Manasen, S., & O’Brien, K., "Sulfamethoxazole-Trimethoprim-Induced Rhabdomyolysis in an Immunocompetent Patient: A Case Report", Medicine, 2014 Jan .
Rezigh, A. B., Armenia, E., Li, T., & Soesilo, I. , "Rifaximin as a rare cause of rhabdomyolysis in cirrhosis", Clinical case reports, 2018 Jan .
Moye, P. M., Manasen, S., & O’Brien, K., "Sulfamethoxazole-Trimethoprim-Induced Rhabdomyolysis in an Immunocompetent Patient: A Case Report", Medicine, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on carisoprodol (the active ingredients of Soma) and Soma (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.